v3.26.3
Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2026
Significant Accounting Policies [Abstract]  
Schedule of Fair Value Measurements on a Recurring Basis

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

 

    September 30, 2026  
    Level 1     Level 2     Level 3     Total  
Assets:                        
Marketable Securities (see note 3):                        
DNA     583       -       -       583  
Nano     10,801       -       -       10,801  
Investments at fair value (see note 4):                                
Ruby Capital     -       -       449       449  
Scilex Royalty Purchase Agreement     -       -       1,749       1,749  
Scilex Tranche A Note     -       -       18,716       18,716  
Scilex Tranche B Note     -       -       4,591       4,591  
Scilex Warrants Note B     -       -       97       97  
Lifeward’s A&R Warrants (see note 8)     -       -       1,675       1,675  
Lifeward’s A&R Note and Note Warrants (see note 8)     -       -       7,857       7,857  
Alpha Tau’s warrants     -       -       36,626       36,626  
Warren at Bay Loan     -       -       2,703       2,703  
83 Wythe Loan     -       -       2,341       2,341  
Profit Sharing Loan Agreement     -       -       3,338       3,338  
Loan agreement measured in fair value (see note 7)     -       -       37,883       37,883  
Loan to an Equity Method Investee (see note 6)     -       -       4       4  
Investment in associates at fair value (see note 8):                                
Alpha Tau’s shares     215,739       -       -       215,739  
Lifeward’s shares     8,252       -       -       8,252  
Lifeward’s A&R Pre-Funded Warrants     -       6,640       -       6,640  
    $ 235,375     $ 6,640     $ 118,029     $ 360,044  
    December 31, 2025  
    Level 1     Level 2     Level 3     Total  
Assets:                        
Marketable Securities (see note 3):                        
DNA     540       -       -       540  
Entera     227       -       -       227  
Pelthos     4,650       -       -       4,650  
Nano     8,371       -       -       8,371  
Investments at fair value (see note 4):                                
Scilex Royalty Purchase Agreement     -       -       2,209       2,209  
Scilex Tranche A Note     -       -       23,063       23,063  
Scilex Warrants Note B     -       -       850       850  
Scilex Tranche B Note     -       -       11,473       11,473  
Loan agreement measured in fair value (see note 7)     -       -       27,943       27,943  
Investment in Alpha Tau’s warrants (see note 8)     -       -       6,242       6,242  
Profit Sharing Loan Agreement     -       -       1,890       1,890  
Investment in Alpha Tau’s shares (see note 8)     71,623       -       -       71,623  
Loan to an equity method investee (see note 6)     -       -       553       553  
Convertible note (see note 8)     -       -       4,636       4,636  
    $ 85,411     $ -     $ 78,859     $ 164,270